Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy |
| |
| Authors: | Cortés K Caraballo T Laskus I Bukowska-Ośko A Pawełczyk H Berak A Horban M Fic M Radkowski |
| |
| Affiliation: | 1. Department of Immunopathology of Infectious and Parasitic Diseases, Medical University of Warsaw, Poland;2. Hospital of Infectious Diseases, Warsaw, Poland;3. Clinical Department of Infectious Diseases, Medical University of Warsaw, Poland;1. Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan;2. Department of Endoscopy, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan;3. Division of Gastroenterology and Hepatology, Omori Medical Center, Toho University School of Medicine, Tokyo, Japan;1. Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Poland;2. Department of Dietetics and Clinical Nutrition, Medical University of Bialystok, Poland;3. Centre of Experimental Medicine, Medical University of Bialystok, Poland;4. Department of Statistics and Medical Informatics, Medical University of Bialystok, Poland;1. Department of Physiology 2, Kawasaki Medical School, Kurashiki, Japan;2. Department of Rehabilitation, Kawasaki University of Medical Welfare, Kurashiki, Japan;3. Department of Physiology 1, Kawasaki Medical School, Kurashiki, Japan;1. University Claude Bernard Lyon, Faculty of Pharmacy, Laboratory of Pharmacology, INSERM team on vascular attacks and tissue responses, Lyon, France;1. Department of Parasitology, Faculty of Biology, University of Warsaw, Warsaw, Poland;2. National Centre for Biosystematics, Natural History Museum, University of Oslo, Blindern, Oslo, Norway;3. Department of Epidemiology, National Institute of Public Health - National Institute of Hygiene, Warsaw, Poland;1. Department of Nephropathology, Medical University of Lodz, Lodz, Poland |
| |
| Abstract: | PurposeGenetic variability of hepatitis C virus (HCV) is considered to be an important factor defining viral pathogenesis, persistence and resistance to treatment. The aim of the present study was to characterize HCV genetic heterogeneity within a hypervariable region 1 (HVR-1) before and during the early period of pegylated interferon alfa (PEG-IFN-α) and ribavirin treatment in correlation with treatment outcome.Material and MethodsThe study involved 24 patients treated with PEG-IFN-α and ribavirin whose sera were collected before (baseline) and at 7, 14, 21 28 and 56 day of treatment. HCV HVR-1 region was amplified by nested RT- PCR and subjected to SSCP (single strand conformational polymorphism) analysis. SSCP changes of HCV HVR-1 over time in each patient were compared to treatment outcome results.ResultsIn 2/11 (18%) SVR+ and 8/13 (62%) SVR- treated patients, HVR-1 genetic changes manifested by new SSCP bands (new genetic variants) and were significantly more frequent in nonresponders (P <0.05).ConclusionsOur results indicate that HCV HVR-1 variability during the early phase of PEG-IFN-α and ribavirin therapy may be predictive of treatment outcome. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
